Actively Recruiting
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Led by University of Aberdeen · Updated on 2026-04-30
70
Participants Needed
2
Research Sites
150 weeks
Total Duration
On this page
Sponsors
U
University of Aberdeen
Lead Sponsor
N
NHS Grampian
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
CONDITIONS
Official Title
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with breast cancer between 18-70 years of age.
- Patients with low to medium cardiovascular risk.
- Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy.
- Patients who are able to give written informed consent to take part in the study.
- Patients who can read and understand English.
You will not qualify if you...
- Patients with a known intolerance of dapagliflozin.
- Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines.
- Patients with significant renal impairment (estimated glomerular filtration rate <45 mL/min/1.73 m2).
- Patients with a previous cancer diagnosis.
- Patients with known type 1 or 2 diabetes mellitus.
- Patients with a contraindication to magnetic resonance imaging.
- Patients with prior exposure to anthracyclines.
- Patients who cannot read and understand English.
- Patients who are pregnant.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cardiac Research Office, Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZD
Actively Recruiting
2
University of Aberdeen
Aberdeen, United Kingdom, AB25 2ZD
Actively Recruiting
Research Team
S
Sylvia Kamya, MBChB
CONTACT
A
Amelia Rudd, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here